Vascular Surgery Research Group, Imperial College, Charing Cross Campus, St Dunstan's Road, London W6 8RF, UK.
Eur J Vasc Endovasc Surg. 2013 Feb;45(2):154-9. doi: 10.1016/j.ejvs.2012.12.007. Epub 2012 Dec 29.
To investigate population trends in thoracic aortic disease (dissections and aneurysms) in England and Wales, with focus on the impact of thoracic endovascular aortic repair on procedure numbers and age at repair.
Routine hospital statistics of England and Wales provided admission, procedure and mortality data from 1999 to 2010. All data were age-standardised, reported per 100,000 population, by age bands (>50 years or 50-74 years versus 75+ years) and gender. Only patients 50+ years were included, to focus on degenerative disease.
Between 1999 and 2010 hospital admissions for total (ascending and descending) have risen steadily for thoracic aortic dissection (TAD) from 7.2 to 8.8 and thoracic aortic aneurysm (TAA) from 4.4 to 9.0, principally attributable to increased admissions in those 75+ years. Total mortality declined steadily over the same period, for TAD from 4.4 to 3.2 and for TAA from 10.4 to 7.5. Procedure rates have risen sharply, driven by the implementation of TEVAR from 2006, for type B dissection from 0.06 to 0.53 and for descending TAA from 0.76 to 1.89. All figures are per 100,000 population with P <0.005.
Improvements in case ascertainment may have contributed to the increase in hospital admissions. The increased application of TEVAR, particularly for dissections, is mainly in those above 75 years and has not yet translated into an accelerated survival benefit.
调查英格兰和威尔士胸主动脉疾病(夹层和动脉瘤)的人群趋势,重点研究胸主动脉腔内修复术对手术数量和修复年龄的影响。
英格兰和威尔士的常规医院统计数据提供了 1999 年至 2010 年的入院、手术和死亡率数据。所有数据均按年龄组(>50 岁或 50-74 岁与 75 岁以上)和性别进行年龄标准化,每 10 万人报告一次。仅纳入 50 岁以上的患者,以关注退行性疾病。
1999 年至 2010 年,胸主动脉夹层(TAD)的总(升主动脉和降主动脉)住院人数稳步上升,从 7.2 例增至 8.8 例,胸主动脉瘤(TAA)从 4.4 例增至 9.0 例,主要归因于 75 岁以上患者的入院人数增加。同期总死亡率稳步下降,TAD 从 4.4 例降至 3.2 例,TAA 从 10.4 例降至 7.5 例。手术率急剧上升,这主要得益于 2006 年开始实施 TEVAR,B 型夹层的手术率从 0.06 例增至 0.53 例,降主动脉 TAA 的手术率从 0.76 例增至 1.89 例。所有数据均为每 10 万人,P<0.005。
病例检出率的提高可能导致住院人数增加。TEVAR 的广泛应用,特别是对夹层的应用,主要集中在 75 岁以上人群,尚未转化为加速生存获益。